Advertisement

Topics

Novartis drug cuts cardiovascular risk in heart attack survivors

06:16 EDT 22 Jun 2017 | PharmaTimes

An experimental antibody being developed by Novartis has cut cardiovascular risk in patients who have survived a heart attack in a late-stage study.

Original Article: Novartis drug cuts cardiovascular risk in heart attack survivors

NEXT ARTICLE

More From BioPortfolio on "Novartis drug cuts cardiovascular risk in heart attack survivors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...